p73 gene alterations and expression in primary oral and laryngeal squamous carcinomas.

p73, a recently identified gene, maps to chromosome region 1p36.3, which is frequently deleted in a variety of solid tumors. Although the gene shares sequence and functional homologies with p53, its suppressor function has not been proven. We investigated for the first time the genetic and expression status of the p73 gene and analyzed its flanking microsatellite loci on chromosome 1p36.3 in 67 primary oral and laryngeal squamous cell carcinomas to determine their association with these tumors. Our results reveal two missense mutations at codons 469 and 477 and a silent mutation at codon 349 in the C-terminal domain. Site-directed mutagenesis of p73 cDNA with these mutations and a p21 transactivation assay failed to show any significant functional consequences of these mutations. Microsatellite analysis of the flanking loci of p73 in region 1p36 showed overall alterations (loss of heterozygosity and instability) frequency of 39%, 16% at the proximal marker and 46% at the distal markers. Of the 21 cases for which we did protein expression analyses, 11 tumors had a >2-fold variation compared with matching histologically normal mucosa. Our study shows that: (i) intragenic alterations in this gene are rare and lack functional significance; (ii) its variable expression argues against a tumor suppressor function; (iii) this gene plays a minor role in head and neck squamous carcinoma; (iv) a distal site to this gene on 1p36 may harbor another suppressor gene.

[1]  G Melino,et al.  The p53/p63/p73 family of transcription factors: overlapping and distinct functions. , 2000, Journal of cell science.

[2]  G. Yang,et al.  Molecular alterations of p73 in human esophageal squamous cell carcinomas: loss of heterozygosity occurs frequently; loss of imprinting and elevation of p73 expression may be related to defective p53. , 2000, Carcinogenesis.

[3]  U. Moll,et al.  Overexpression of the wild type p73 gene in breast cancer tissues and cell lines. , 1999, Cancer research.

[4]  A. Nakagawara,et al.  Identification of a transactivation activity in the COOH-terminal region of p73 which is impaired in the naturally occurring mutants found in human neuroblastomas. , 1999, Cancer research.

[5]  S. Chi,et al.  Elevated and biallelic expression of p73 is associated withprogression of human bladder cancer. , 1999, Cancer research.

[6]  W. Kaelin,et al.  MDM2 Suppresses p73 Function without Promoting p73 Degradation , 1999, Molecular and Cellular Biology.

[7]  D. Tindall,et al.  Mutation and expression analysis of the p73 gene in prostate cancer , 1999, The Prostate.

[8]  A. Jochemsen,et al.  Distinct Regulation of p53 and p73 Activity by Adenovirus E1A, E1B, and E4orf6 Proteins , 1999, Molecular and Cellular Biology.

[9]  W. Kaelin.  The emerging p53 gene family. , 1999, Journal of the National Cancer Institute.

[10]  D. Tindall,et al.  Overexpression of the wild type p73 gene in human bladder cancer , 1999, Oncogene.

[11]  C. Prives,et al.  p73 Function Is Inhibited by Tumor-Derived p53 Mutants in Mammalian Cells , 1999, Molecular and Cellular Biology.

[12]  C. Prives,et al.  The p53 pathway , 1999, The Journal of pathology.

[13]  C. Lo Cunsolo,et al.  Refined chromosomal localization of the putative tumor suppressor gene TP73 , 1998, Cytogenetic and Genome Research.

[14]  N. Nomura,et al.  p73, a geme related to p53, is not mutated in esophageal carcinomas , 1998, International journal of cancer.

[15]  G. Melino,et al.  Two New p73 Splice Variants, γ and δ, with Different Transcriptional Activity , 1998, Journal of Experimental Medicine.

[16]  H. Koeffler,et al.  Chromosome band 1p36 contains a putative tumor suppressor gene important in the evolution of chronic myelocytic leukemia. , 1998, Blood.

[17]  W. Kaelin,et al.  Viral Oncoproteins Discriminate between p53 and the p53 Homolog p73 , 1998, Molecular and Cellular Biology.

[18]  S. Swendeman,et al.  Expression level, allelic origin, and mutation analysis of the p73 gene in neuroblastoma tumors and cell lines. , 1998, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.

[19]  David I. Smith,et al.  Loss of imprinting and allele switching of p73 in renal cell carcinoma , 1998, Oncogene.

[20]  W. Liu,et al.  Genomic organization and mutation analysis of p73 in oligodendrogliomas with chromosome 1 p-arm deletions. , 1998, Genomics.

[21]  J. Jen,et al.  A new human p53 homologue , 1998, Nature Medicine.

[22]  Chikashi Ishioka,et al.  Cloning and functional analysis of human p51, which structurally and functionally resembles p53 , 1998, Nature Medicine.

[23]  R. Kurzbauer,et al.  Molecular cloning and expression analysis of five novel genes in chromosome 1p36. , 1998, Genomics.

[24]  D. Tindall,et al.  Activation of p73 silent allele in lung cancer. , 1998, Cancer research.

[25]  A. El‐Naggar,et al.  The prognostic significance of the biomarkers p21WAF1/CIP1, p53, and bcl‐2 in laryngeal squamous cell carcinoma , 1998, Cancer.

[26]  T. Matise,et al.  Report and abstracts of the third international workshop on human chromosome 1 mapping 1997. , 1997, Cytogenetics and cell genetics.

[27]  A. El‐Naggar,et al.  Methylation, a major mechanism of p16/CDKN2 gene inactivation in head and neck squamous carcinoma. , 1997, The American journal of pathology.

[28]  J. Biegel,et al.  Molecular analysis of the region of distal 1p commonly deleted in neuroblastoma. , 1997, European journal of cancer.

[29]  S. Dickman.  First p53 Relative May Be a New Tumor Suppressor , 1997, Science.

[30]  W. Kaelin,et al.  p73 is a human p53-related protein that can induce apoptosis , 1997, Nature.

[31]  M. Oren.  Lonely No More: p53 Finds Its Kin in a Tumor Suppressor Haven , 1997, Cell.

[32]  A. Yang,et al.  Monoallelically Expressed Gene Related to p53 at 1p36, a Region Frequently Deleted in Neuroblastoma and Other Human Cancers , 1997, Cell.

[33]  A. El‐Naggar,et al.  HER-2/neu oncogene characterization in head and neck squamous cell carcinoma. , 1995, Archives of otolaryngology--head & neck surgery.

[34]  J. Herman,et al.  Inactivation of the CDKN2/p16/MTS1 gene is frequently associated with aberrant DNA methylation in all common human cancers. , 1995, Cancer research.

[35]  J. Batsakis,et al.  Sequential loss of heterozygosity at microsatellite motifs in preinvasive and invasive head and neck squamous carcinoma. , 1995, Cancer research.

[36]  J. Klijanienko,et al.  Tumor vascularization, mitotic index, histopathologic grade, and DNA ploidy in the assessment of 114 head and neck squamous cell carcinomas , 1995, Cancer.

[37]  R H Hruban,et al.  Association between cigarette smoking and mutation of the p53 gene in squamous-cell carcinoma of the head and neck. , 1995, The New England journal of medicine.

[38]  J. Fraumeni,et al.  Recent Cancer Trends in the United States , 1995 .

[39]  A. Balmain,et al.  An allelotype of squamous carcinoma of the head and neck using microsatellite markers. , 1994, Cancer research.

[40]  R. Hruban,et al.  Allelotype of head and neck squamous cell carcinoma. , 1994, Cancer research.

[41]  F. Haluska,et al.  Mutational and expression analysis of the p73 gene in melanoma cell lines. , 1999, Cancer research.

[42]  D. Spandidos,et al.  p53 expression and mutations in squamous cell carcinoma of the head and neck: expression correlates with the patients' use of tobacco and alcohol. , 1994, Cancer detection and prevention.

[43]  J. Nickoloff,et al.  Site-directed mutagenesis of virtually any plasmid by eliminating a unique site. , 1992, Analytical biochemistry.